Symbols / ABVC $1.32 +3.94%
ABVC Chart
About
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 33.58M |
| Enterprise Value | 37.53M | Income | -7.91M | Sales | — |
| Book/sh | 0.46 | Cash/sh | 0.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 16 | IPO | — |
| P/E | — | Forward P/E | -3.00 | PEG | — |
| P/S | — | P/B | 2.89 | P/C | — |
| EV/EBITDA | -5.27 | EV/Sales | — | Quick Ratio | 0.12 |
| Current Ratio | 0.41 | Debt/Eq | 26.12 | LT Debt/Eq | — |
| EPS (ttm) | -0.39 | EPS next Y | -0.44 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-05-15 16:00 | ROA | -31.25% |
| ROE | -119.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 3.76% | Profit Margin | 0.00% | Shs Outstand | 25.44M |
| Shs Float | 19.88M | Short Float | 1.15% | Short Ratio | 4.50 |
| Short Interest | — | 52W High | 5.48 | 52W Low | 0.65 |
| Beta | 0.27 | Avg Volume | 60.17K | Volume | 26.05K |
| Target Price | — | Recom | None | Prev Close | $1.27 |
| Price | $1.32 | Change | 3.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.32
Latest analyst target
3. DCF / Fair value
$0.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.32
Low
—
High
—
Mean
—
- Restatement and asset surge reshape ABVC BioPharma (NASDAQ: ABVC) - Stock Titan ue, 03 Mar 2026 21
- ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025 - Yahoo Finance Mon, 03 Nov 2025 08
- ABVC SEC Filings - Abvc Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 21
- ABVC BioPharma, Inc. (ABVC) Reports 103% Asset Surge, Eyeing Phase III Trials for Depression Therapies - Yahoo Finance ue, 23 Sep 2025 07
- ABVC BioPharma - quarterly period ended September, 2025 financial statements should not be relied upon - marketscreener.com ue, 03 Mar 2026 08
- ABVC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 14 Feb 2026 13
- AiBtl signs $667m licensing deal for ABVC’s CNS drug - Pharmaceutical Technology Fri, 17 Nov 2023 08
- ABVC BioPharma faces Nasdaq delisting over share price - Investing.com Fri, 12 Jul 2024 07
- ABVC Stock Price and Chart — NASDAQ:ABVC - TradingView Mon, 02 Aug 2021 07
- What is the current Price Target and Forecast for ABVC BIOPHARMA (ABVC) - Zacks Investment Research Fri, 11 Nov 2022 18
- Tiny U.S. Biotech Jumps 930% as It Picks Up Retail Attention - Bloomberg.com Mon, 01 Nov 2021 07
- ABVC BioPharma Announces Reverse Stock Split - Yahoo Finance Mon, 24 Jul 2023 07
- ABVC BioPharma secures global licensing deal - Investing.com UK ue, 26 Mar 2024 07
- ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - Yahoo Finance hu, 15 Aug 2024 07
- ABVC - Abvc Biopharma Inc Latest Stock News & Market Updates - Stock Titan hu, 05 Aug 2021 01
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -225.40K | -2.24K | -41.83K | -79.18K |
| TaxRateForCalcs | 0.21 | 0.02 | 0.21 | 0.21 |
| NormalizedEBITDA | -6.36M | -4.23M | -6.13M | -14.82M |
| TotalUnusualItems | -1.07M | -108.71K | -199.20K | -377.03K |
| TotalUnusualItemsExcludingGoodwill | -1.07M | -108.71K | -199.20K | -377.03K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.91M | -4.90M | -7.79M | -16.42M |
| ReconciledDepreciation | 504.83K | 200.92K | 380.39K | 23.80K |
| ReconciledCostOfRevenue | 0.00 | 763.00 | 302.04K | 286.42K |
| EBITDA | -7.43M | -4.34M | -6.33M | -15.20M |
| EBIT | -7.94M | -4.54M | -6.71M | -15.22M |
| NetInterestIncome | -248.79K | -738.54K | -1.13M | -106.15K |
| InterestExpense | 415.89K | 825.90K | 1.31M | 293.97K |
| InterestIncome | 167.10K | 87.36K | 185.48K | 187.82K |
| NormalizedIncome | -7.06M | -4.80M | -7.63M | -16.13M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.91M | -4.90M | -7.79M | -16.42M |
| TotalExpenses | 7.15M | 5.21M | 6.92M | 16.08M |
| TotalOperatingIncomeAsReported | -7.15M | -4.71M | -6.77M | -15.11M |
| DilutedAverageShares | 11.67M | 4.34M | 3.17M | 2.51M |
| BasicAverageShares | 11.67M | 4.34M | 3.17M | 2.51M |
| DilutedEPS | -0.42 | -1.80 | -5.20 | -5.10 |
| BasicEPS | -0.42 | -1.80 | -5.20 | -5.10 |
| DilutedNIAvailtoComStockholders | -7.91M | -4.90M | -7.79M | -16.42M |
| NetIncomeCommonStockholders | -7.91M | -4.90M | -7.79M | -16.42M |
| NetIncome | -7.91M | -4.90M | -7.79M | -16.42M |
| MinorityInterests | 468.40K | 356.16K | 492.79K | -110.86K |
| NetIncomeIncludingNoncontrollingInterests | -8.38M | -5.26M | -8.28M | -16.31M |
| NetIncomeContinuousOperations | -8.38M | -5.26M | -8.28M | -16.31M |
| TaxProvision | 24.15K | -110.54K | 256.01K | 797.78K |
| PretaxIncome | -8.35M | -5.37M | -8.02M | -15.51M |
| OtherIncomeExpense | -952.76K | 74.21K | -129.91K | -294.03K |
| OtherNonOperatingIncomeExpenses | 120.55K | 182.92K | 69.28K | 83.00K |
| SpecialIncomeCharges | -803.01K | 255.59K | 0.00 | -110.12K |
| OtherSpecialCharges | -255.59K | |||
| WriteOff | 803.01K | 0.00 | 0.00 | 110.12K |
| GainOnSaleOfSecurity | -270.31K | -364.31K | -199.20K | -266.91K |
| NetNonOperatingInterestIncomeExpense | -248.79K | -738.54K | -1.13M | -106.15K |
| InterestExpenseNonOperating | 415.89K | 825.90K | 1.31M | 293.97K |
| InterestIncomeNonOperating | 167.10K | 87.36K | 185.48K | 187.82K |
| OperatingIncome | -7.15M | -4.71M | -6.77M | -15.11M |
| OperatingExpense | 7.15M | 5.21M | 6.62M | 15.80M |
| OtherOperatingExpenses | -360.90K | |||
| ResearchAndDevelopment | 121.08K | 179.27K | 1.06M | 2.69M |
| SellingGeneralAndAdministration | 7.03M | 5.03M | 5.55M | 13.10M |
| GeneralAndAdministrativeExpense | 7.03M | 5.03M | 5.55M | 13.10M |
| OtherGandA | 2.89M | 2.26M | 5.37M | 6.07M |
| SalariesAndWages | 4.14M | 2.77M | 185.93K | 7.04M |
| GrossProfit | 0.00 | 508.83K | -149.61K | 683.37K |
| CostOfRevenue | 0.00 | 763.00 | 302.04K | 286.42K |
| TotalRevenue | 0.00 | 509.59K | 152.43K | 969.78K |
| OperatingRevenue | 0.00 | 509.59K | 152.43K | 969.78K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 730.64K | 730.64K | 26.55K | 27.53K |
| OrdinarySharesNumber | 24.32M | 13.14M | 7.91M | 3.29M |
| ShareIssued | 25.05M | 13.87M | 7.94M | 3.31M |
| NetDebt | 873.04K | 1.54M | 1.73M | 1.81M |
| TotalDebt | 3.47M | 2.43M | 2.60M | 3.05M |
| TangibleBookValue | 11.11M | 1.23M | 1.55M | 3.10M |
| InvestedCapital | 12.67M | 3.02M | 3.34M | 4.99M |
| WorkingCapital | -3.66M | -4.38M | -4.45M | -2.56M |
| NetTangibleAssets | 11.11M | 1.23M | 1.55M | 3.10M |
| CapitalLeaseObligations | 1.92M | 640.39K | 809.28K | 1.16M |
| CommonStockEquity | 11.11M | 1.23M | 1.55M | 3.10M |
| TotalCapitalization | 11.11M | 1.23M | 1.55M | 3.10M |
| TotalEquityGrossMinorityInterest | 13.30M | 723.96K | 1.25M | 3.24M |
| MinorityInterest | 2.19M | -502.18K | -300.64K | 137.55K |
| StockholdersEquity | 11.11M | 1.23M | 1.55M | 3.10M |
| OtherEquityInterest | 359.00K | 31.04K | -451.48K | -1.35M |
| GainsLossesNotAffectingRetainedEarnings | 487.60K | 445.67K | 516.39K | 517.13K |
| OtherEquityAdjustments | 487.60K | 445.67K | 516.39K | 517.13K |
| TreasuryStock | 8.91M | 8.91M | 8.90M | 9.10M |
| RetainedEarnings | -76.86M | -68.95M | -64.05M | -54.90M |
| AdditionalPaidInCapital | 96.01M | 78.60M | 73.98M | 67.94M |
| CapitalStock | 25.05K | 13.87K | 7.94K | 3.29K |
| CommonStock | 25.05K | 13.87K | 7.94K | 3.29K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 7.76M | 6.82M | 6.53M | 6.34M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.60M | 258.49K | 429.14K | 799.81K |
| OtherNonCurrentLiabilities | 21.68K | 21.68K | 7.98K | 10.58K |
| LongTermDebtAndCapitalLeaseObligation | 1.60M | 236.81K | 407.46K | 791.83K |
| LongTermCapitalLeaseObligation | 1.60M | 236.81K | 407.46K | 791.83K |
| CurrentLiabilities | 6.16M | 6.56M | 6.10M | 5.54M |
| OtherCurrentLiabilities | 470.13K | 430.11K | 427.35K | 468.15K |
| CurrentDeferredLiabilities | 12.60K | 81.11K | 79.50K | 10.98K |
| CurrentDeferredRevenue | 12.60K | 81.11K | 79.50K | 10.98K |
| CurrentDebtAndCapitalLeaseObligation | 1.87M | 2.19M | 2.19M | 2.26M |
| CurrentCapitalLeaseObligation | 317.56K | 403.58K | 401.83K | 369.31K |
| CurrentDebt | 1.55M | 1.79M | 1.79M | 1.89M |
| OtherCurrentBorrowings | 799.01K | 950.05K | 886.52K | 186.88K |
| LineOfCredit | 725.51K | 810.25K | 899.25K | 1.89M |
| CurrentNotesPayable | 30.00K | 30.00K | 0.00 | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.45M | 1.15M | 1.05M | 568.87K |
| PayablesAndAccruedExpenses | 2.36M | 2.70M | 2.36M | 2.23M |
| CurrentAccruedExpenses | 2.25M | 1.93M | 2.07M | 1.87M |
| Payables | 117.67K | 773.04K | 286.44K | 359.99K |
| DuetoRelatedPartiesCurrent | 105.70K | 773.04K | 173.49K | 359.99K |
| TotalTaxPayable | 11.96K | 0.00 | 112.95K | 0.00 |
| AccountsPayable | 0.00 | |||
| TotalAssets | 21.06M | 7.54M | 7.78M | 9.58M |
| TotalNonCurrentAssets | 18.56M | 5.36M | 6.13M | 6.59M |
| OtherNonCurrentAssets | 116.97K | 133.12K | 141.23K | |
| NonCurrentPrepaidAssets | 1.82M | 1.82M | 1.97M | 3.03M |
| NonCurrentDeferredAssets | 0.00 | 117.11K | 981.91K | |
| NonCurrentDeferredTaxesAssets | 0.00 | 117.11K | 981.91K | |
| DuefromRelatedPartiesNonCurrent | 0.00 | 113.52K | 865.48K | 818.18K |
| NonCurrentAccountsReceivable | 113.52K | 865.48K | 818.18K | |
| InvestmentsAndAdvances | 1.88M | 2.26M | 2.53M | 842.07K |
| OtherInvestments | 847.25K | 842.07K | ||
| InvestmentinFinancialAssets | 28.74K | 790.25K | 847.25K | 842.07K |
| AvailableForSaleSecurities | 28.74K | 790.25K | 847.25K | 842.07K |
| LongTermEquityInvestment | 1.85M | 1.47M | 1.68M | 0.00 |
| InvestmentsinJointVenturesatCost | 0.00 | 0.00 | ||
| InvestmentsinAssociatesatCost | 1.85M | 1.47M | 1.68M | 0.00 |
| GoodwillAndOtherIntangibleAssets | 0.00 | |||
| Goodwill | 0.00 | |||
| NetPPE | 14.75M | 1.15M | 1.38M | 1.74M |
| AccumulatedDepreciation | -3.38M | -3.34M | -3.34M | -3.30M |
| GrossPPE | 18.13M | 4.49M | 4.71M | 5.04M |
| ConstructionInProgress | 7.40M | 0.00 | ||
| OtherProperties | 1.91M | 640.39K | 809.28K | 1.16M |
| MachineryFurnitureEquipment | 1.31M | 1.29M | 1.31M | 1.29M |
| BuildingsAndImprovements | 2.22M | 2.22M | 2.23M | 2.23M |
| LandAndImprovements | 12.69M | 338.97K | 363.42K | 361.19K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.50M | 2.18M | 1.66M | 2.99M |
| OtherCurrentAssets | 346.62K | 96.21K | 101.05K | 150.24K |
| RestrictedCash | 645.50K | 615.43K | 656.62K | 1.31M |
| PrepaidAssets | 1.21M | |||
| Inventory | 0.00 | 25.98K | ||
| InventoriesAdjustmentsAllowances | 0.00 | -155.37K | ||
| FinishedGoods | 0.00 | 96.72K | ||
| WorkInProcess | 0.00 | 0.00 | ||
| RawMaterials | 0.00 | 84.62K | ||
| Receivables | 763.39K | 1.16M | 759.57K | 1.37M |
| DuefromRelatedPartiesCurrent | 763.39K | 1.16M | 758.04K | 1.27M |
| AccountsReceivable | 0.00 | 1.53K | 98.33K | 280.69K |
| AllowanceForDoubtfulAccountsReceivable | -616.41K | -616.50K | ||
| GrossAccountsReceivable | 616.41K | 618.03K | ||
| CashCashEquivalentsAndShortTermInvestments | 745.83K | 313.12K | 139.47K | 161.06K |
| OtherShortTermInvestments | 64.35K | 64.74K | 79.31K | 75.80K |
| CashAndCashEquivalents | 681.48K | 248.38K | 60.16K | 85.27K |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.99M | -1.81M | -4.21M | -7.52M |
| RepurchaseOfCapitalStock | 0.00 | -7.32K | 0.00 | |
| RepaymentOfDebt | -547.68K | -356.17K | -1.00M | 0.00 |
| IssuanceOfDebt | 889.01K | 372.10K | 1.46M | 350.00K |
| IssuanceOfCapitalStock | 3.31M | 31.04K | 1.05M | 3.66M |
| CapitalExpenditure | -21.20K | -119.69K | -17.50K | |
| InterestPaidSupplementalData | 31.52K | 22.54K | 33.18K | 285.46K |
| IncomeTaxPaidSupplementalData | 12.08K | 25.86K | 27.39K | 1.60K |
| EndCashPosition | 1.33M | 863.82K | 716.78K | 1.39M |
| BeginningCashPosition | 863.82K | 716.78K | 1.39M | 6.57M |
| EffectOfExchangeRateChanges | 20.26K | -24.59K | 2.12K | -67.34K |
| ChangesInCash | 442.91K | 171.62K | -677.07K | -5.11M |
| FinancingCashFlow | 4.64M | 1.98M | 3.87M | 4.01M |
| CashFlowFromContinuingFinancingActivities | 4.64M | 1.98M | 3.87M | 4.01M |
| NetOtherFinancingCharges | 599.55K | -49.00K | -850.43K | |
| ProceedsFromStockOptionExercised | 991.37K | 1.34M | 2.41M | 0.00 |
| NetCommonStockIssuance | 3.31M | 23.72K | 1.05M | 3.66M |
| CommonStockPayments | 0.00 | -7.32K | 0.00 | |
| CommonStockIssuance | 3.31M | 31.04K | 1.05M | 3.66M |
| NetIssuancePaymentsOfDebt | 341.33K | 15.93K | 462.62K | 350.00K |
| NetShortTermDebtIssuance | 378.61K | 312.94K | 462.62K | 350.00K |
| ShortTermDebtPayments | -120.40K | -29.15K | -1.00M | 0.00 |
| ShortTermDebtIssuance | 499.01K | 342.10K | 1.46M | 350.00K |
| NetLongTermDebtIssuance | -37.28K | -297.02K | 0.00 | 0.00 |
| LongTermDebtPayments | -427.28K | -327.02K | 0.00 | 0.00 |
| LongTermDebtIssuance | 390.00K | 30.00K | 0.00 | 0.00 |
| InvestingCashFlow | -1.21M | 0.00 | -360.19K | -1.72M |
| CashFlowFromContinuingInvestingActivities | -1.21M | 0.00 | -360.19K | -1.72M |
| NetOtherInvestingChanges | -1.20M | |||
| NetInvestmentPurchaseAndSale | 0.00 | -107.55K | ||
| SaleOfInvestment | 0.00 | |||
| PurchaseOfInvestment | 0.00 | -107.55K | ||
| NetInvestmentPropertiesPurchaseAndSale | -5.79K | 0.00 | ||
| PurchaseOfInvestmentProperties | -5.79K | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | -338.99K | -1.60M | -680.92K |
| PurchaseOfBusiness | 0.00 | -338.99K | -1.60M | -680.92K |
| NetPPEPurchaseAndSale | 0.00 | -21.20K | -119.69K | -17.50K |
| PurchaseOfPPE | 0.00 | -21.20K | -119.69K | -17.50K |
| OperatingCashFlow | -2.99M | -1.81M | -4.19M | -7.40M |
| CashFlowFromContinuingOperatingActivities | -2.99M | -1.81M | -4.19M | -7.40M |
| ChangeInWorkingCapital | -615.30K | -408.42K | 490.77K | 635.57K |
| ChangeInOtherWorkingCapital | -85.38K | 1.61K | 82.22K | -2.60K |
| ChangeInOtherCurrentLiabilities | -474.48K | -168.90K | -351.86K | -2.60K |
| ChangeInPayablesAndAccruedExpense | 164.17K | 39.87K | 751.71K | 1.85M |
| ChangeInAccruedExpense | 152.21K | 152.82K | 638.76K | 1.61M |
| ChangeInInterestPayable | -2.60K | 0.00 | ||
| ChangeInPayable | 11.96K | -112.95K | 112.95K | 242.47K |
| ChangeInAccountPayable | 0.00 | -23.04K | ||
| ChangeInTaxPayable | 11.96K | -112.95K | 112.95K | 0.00 |
| ChangeInIncomeTaxPayable | 11.96K | -112.95K | 112.95K | 0.00 |
| ChangeInPrepaidAssets | -71.65K | 12.95K | 101.93K | 238.09K |
| ChangeInInventory | -11.46K | 0.00 | 0.00 | -25.83K |
| ChangeInReceivables | -136.50K | -293.96K | -93.22K | -1.45M |
| ChangesInAccountReceivables | 0.00 | 228.56K | -614.17K | -120.98K |
| OtherNonCashItems | 351.08K | 532.77K | 1.24M | 32.35K |
| StockBasedCompensation | 4.14M | 2.77M | 185.93K | 7.04M |
| ProvisionandWriteOffofAssets | 0.00 | 11.99K | 1.46M | 210.56K |
| AssetImpairmentCharge | 814.47K | 0.00 | 0.00 | 110.12K |
| DeferredTax | 0.00 | 115.67K | 864.80K | 824.20K |
| DeferredIncomeTax | 0.00 | 115.67K | 864.80K | 824.20K |
| DepreciationAmortizationDepletion | 504.83K | 200.92K | 380.39K | 23.80K |
| DepreciationAndAmortization | 504.83K | 200.92K | 380.39K | 23.80K |
| Depreciation | 504.83K | 200.92K | 380.39K | 23.80K |
| OperatingGainsLosses | 192.76K | 339.17K | 221.89K | 269.84K |
| GainLossOnInvestmentSecurities | 192.76K | 339.17K | 221.89K | 269.84K |
| NetIncomeFromContinuingOperations | -8.38M | -5.26M | -8.28M | -16.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABVC
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|